Back to search

United Kingdom· GB-APID-14605511000001104

Baraclude 0.05mg/ml oral solution

A entecavir product containing entecavir, registered in United Kingdom by Bristol-Myers Squibb Pharmaceuticals Ltd. The same ATC class is registered in 17 of our 19 countries.

ATC J05AF10

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedBaraclude 0.05mg/ml oral solutionATCJ05AF10REGISTER NO.GB-APID-1460551100000…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Entecavir is registered in 17 of 19 countries.

Countries holding a registration under ATC J05AF10 (entecavir), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 10 of them publish a price we can compare per daily dose

Entecavir · ATC J05AF10

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of entecavir costs, country by country.

Normalised to the WHO defined daily dose (0.5 mg), the median price runs from $0.20 in United States to $12.37 in Switzerland — a ×61 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Entecavir · price per daily dose (0.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$12.37
  • FR France$7.50
  • IT Italy$4.93
  • US United States$0.20 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Entecavir
Manufacturer
Bristol-Myers Squibb Pharmaceuticals Ltd
Country
United Kingdom (GB)
ATC code
J05AF10
ATC class
Entecavir
Defined daily dose
0.5 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    5012712003694
  • gtin
    05012712003694

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

56 interactions on record for entecavir.

Graded by severity as the source publishes them — 56 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Entecavir · interactions on record

56 records

  • 56 moderate

Most severe, free to view

  • CimetidineA02BA01moderate
  • RanitidineA02BA02moderate
  • FamotidineA02BA03moderate
  • NeomycinA07AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Entecavir in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All entecavir products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Austria · Entecavir Ratiopharm
  • Bulgaria · Ентекавир Pharmascience International Ltd, Ентекавир Зентива
  • Cyprus · Entevirem
  • Czechia · Entecavir Fmk, Entecavir Sandoz
  • Germany · Entecavir Al, Entecavir Amarox
  • Denmark · Edevira, Entecavir Medical Valley
  • Spain · Entecavir Aurovitas, Entecavir Dr. Reddys
  • Finland · Entecavir Stada
  • France · Entecavir Arrow, Entecavir Biogaran
  • Greece · Edevira, Entecavir Sandoz
  • Hungary · Entecavir Pharmascience International Ltd, Entecavir Teva
  • Iceland · Baraclude, Entecavir Accord
  • Italy · Entecavir Aristo, Entecavir Aurobindo
  • Liechtenstein · Baraclude, Entecavir Accord
  • Lithuania · Entecavir Sandoz
  • Malta · Entecavir Dr. Reddy's, Entecavir Normon
  • Netherlands · Entecavir Amarox, Entecavir Aurobindo
  • Norway · Baraclude, Entecavir Accord
  • Poland · Entecavir Aurovitas, Entecavir Polpharma
  • Portugal · Entecavir Farmoz, Entecavir Generis
  • Romania · Entecavir Labormed, Entecavir Sandoz
  • Sweden · Entecavir Amarox, Entecavir Medical Valley
  • Slovenia · Entekavir Sandoz, Entekavir Stada
  • Slovakia · Entecavir Fmk

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ef8cf255-67be-46bd-ade0-2943071a0f7c
GET /v1/drugs/ef8cf255-67be-46bd-ade0-2943071a0f7c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "14605511000001104",
  "desc": "Baraclude 0.05mg/ml oral solution (Bristol-Myers Squibb Pharmaceuticals Ltd)",
  "form": "Oral solution",
  "vpid": "14605911000001106",
  "source": "dmd",
  "vtm_id": "775774002",
  "strength": "50 microgram",
  "substance": "Entecavir",
  "ingredient": "Entecavir monohydrate",
  "supplier_code": "3145301000001104"
}

See everything about entecavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.